# Nolan Capital

> Nolan Capital is a VC fund in Hermosa Beach backing Biotechnology and Genetics. See 8 investments, round sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Hermosa Beach, United States
- Total investments: 8
- Last investment: Jan 2023
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/nolan-capital-inc./
- Website: http://www.nolancap.com/

Nolan Capital is a real estate and other investments company located in Hermosa Beach.

## Contacts

5 contacts available for Nolan Capital. Shizune tracks 1 team members at Nolan Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/nolan-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 50% |
| Genetics | 2 | 25% |
| Health Care | 2 | 25% |
| Life Science | 2 | 25% |
| Therapeutics | 2 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 25% |
| Series D | 2 | 25% |
| Seed | 1 | 13% |
| Series C | 1 | 13% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Peter Nolan | President | 0 | — |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Palvella Therapeutics | Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania. | $37.7M | Series D | Jan 05, 2023 |  |
| Jaguar Gene Therapy | Jaguar Gene Therapy is accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. | $139M | Series B | Apr 13, 2021 |  |
| Taysha Gene Therapies | Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. Wehave combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. | $95M | Series B | Aug 05, 2020 |  |
| Taysha Gene Therapies | Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. Wehave combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. | $95M | Series B | Aug 05, 2020 |  |
| Encoded Therapeutics | Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad range of severe genetic disorders. The company's therapy pipeline addresses devastating genetic and acquired disorders spanning multiple disease pathways including neurocircuitry, metabolic disorders, neurodegeneration and cardiovasculardisease, enabling medical practitioners to treat patients and improve their lives. | $135M | Series D | Jul 22, 2020 |  |
| Palvella Therapeutics | Palvella Therapeutics is a start-up life sciences company that focuses on relentlessly and selflessly serving abandoned patient populations with therapies. The company specializes in developing therapies that specifically target the root cause of the disease. Palvella Therapeutics was founded in 2015 and headquartered in Wayne, Pennsylvania. | $45M | Series C | May 28, 2020 |  |
| Taysha Gene Therapies | Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. Wehave combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. | $30M | Seed | Apr 29, 2020 |  |
| Taysha Gene Therapies | Taysha Gene Therapies is a developer of treatments to eradicate severe & life-threatening monogenic diseases of the central nervous system. Taysha Gene Therapies is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we are able to rapidly translate our treatments from bench to bedside. Wehave combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to quickly and efficiently build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. | $30M | Seed | Apr 29, 2020 |  |

8 of 8 investments shown.

## Co-investors
- [Google Ventures](https://shizune.co/investors/profile/google-ventures) — VC Fund, 8 deals together
- PBM Capital Group — VC Fund, 4 deals together
- [Agent Capital](https://shizune.co/investors/profile/agent-capital) — VC Fund, 2 deals together
- [ArrowMark Partners](https://shizune.co/investors/profile/arrowpoint-partners) — VC Fund, 2 deals together
- [BioAdvance](https://shizune.co/investors/profile/bioadvance) — VC Fund, 2 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Nolan Capital invest in?

Nolan Capital invests primarily in Biotechnology, Genetics and Health Care startups, most often at Series B and Series D stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Nolan Capital?

Public channels for Nolan Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Nolan Capital?

The team at Nolan Capital includes Peter Nolan (President). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co